TOMI Environmental Solutions, Inc.

Revenue for Q2 2026 was $2.25 million, up 118% from $1.03 million in Q2 2025 and up 36% from $1.65 million in Q1 2026. Gross profit was $1.39 million, up 105% year over year, and gross margin was 61.7% versus 50.3% in Q1 2026 and 65.7% in Q2 2025. Operating expenses were $1.63 million, down 10% year over year, and operating loss improved to about $244,000 from about $1.13 million a year ago. Net loss was approximately $382,000, or $0.05 per share, versus about $1.24 million, or $0.19 per share, in Q2 2025. For the first half, revenue was not explicitly stated, but management said BIT Solution sales exceeded $700,000 and net loss improved 20% to about $1.19 million. Cash and cash equivalents were $322,000, working capital was $1.82 million, stockholders’ equity was $1.43 million, and the company said it had about $18.1 million of remaining ELOC capacity. Backlog was $2.2 million at quarter end and $2.6 million post-quarter; booked orders and expected completions before year-end exceeded $6.2 million, with an active integrated project pipeline of $4.3 million across 13 projects and a broader commercial sales pipeline of about $35 million. Management reaffirmed full-year 2026 revenue guidance of at least $12 million and said it expects to reach breakeven comfortably by Q4.

Dr. Halden Shane framed the quarter as proof that SteraMist is gaining traction, pointing to three consecutive quarters of growth, a rising backlog, and broader adoption across healthcare, food safety, government, and international markets. He emphasized the strategic importance of the Carbonium Core merger, the expanding regulatory footprint in Europe, and the new AgriMist EPA label, while also discussing longer-term ambitions such as robotics, drones, and biodefense applications. His tone was notably upbeat and expansive, with a strong focus on future platform potential.

Niro Srirathan highlighted the hard numbers behind the quarter: revenue of $2.25 million, gross margin of 61.7%, operating expenses of $1.63 million, and net loss of about $382,000, all while cash rose to $322,000 and working capital increased to $1.82 million. He noted approximately $300,000 in elevated advisory, legal, and diligence costs tied to the Carbonium Core transaction, said the company had about $18.1 million of remaining ELOC capacity, and disclosed a post-quarter amendment lowering convertible note conversion price from $3.75 to $1.50 per share. He also reiterated at least $12 million in full-year revenue guidance and said the company expects to reach operating breakeven by Q4.

Analysts focused on the timeline for the 510(k) medical device pathway, with management saying the next steps involve studies with one customer base and that it is too early to give a firm 12- or 18-month estimate. Questions also centered on the Carbonium merger, where management said two conditions matter: NASDAQ listing compliance and raising $10 million for the combined companies; they added that Carbonium is still in prototype development but has contracts in final stages with Oak Ridge Nuclear and the Department of Energy. Other questions covered FEMA, tariffs, the hybrid system, and the path to profitability; management said FEMA has been a long-term customer, they were not aware of tariffs currently affecting the company, and breakeven by Q4 should be supported by revenue growth and cost cutting.